nanotech-investing Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
nanotech-investing Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
nanotech-investing Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
nanotech-investing Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
nanotech-investing Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
nanotech-investing Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
nanotech-investing Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
nanotech-investing NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
nanotech-investing Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
nanotech-investing Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
nanotech-investing Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
